Managing Breakthrough Pain: A Clinical Review With Three Case Studies Using Oral Transmucosal Fentanyl Citrate
Authors:
- Michelle RhinerMRMichelle Rhiner
- Guadalupe PalosGPGuadalupe Palos
- Maria TerminiMTMaria Termini
- 1 October 2004
- journal article
- case report
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 8 (5) , 507-12
Abstract
Pain management begins with the use of appropriate assessment tools and includes planning, implementing, and evaluating a comprehensive treatment plan that addresses persistent and breakthrough pain. Persistent pain is present to some degree throughout the day and primarily is controlled with around-the-clock medication. However, it often is accompanied by episodes of short, intermittent pain, also known as breakthrough pain. From a clinical perspective, breakthrough pain is characterized as a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy. Breakthrough pain typically is moderate to severe in intensity and can be triggered by various activities (incident pain), be entirely unpredictable (idiopathic pain), or occur toward the end of around-the-clock medication (end-of-dose failure). Breakthrough pain occurs in as many as 86% of patients with cancer even when persistent pain is well controlled. Clinicians and patients should address persistent and breakthrough pain as distinct entities to accurately assess it and develop appropriate pain management plans. This article provides an overview of the clinical characteristics of persistent and breakthrough pain and, through the use of three case studies, illustrates practical strategies for managing breakthrough pain effectively.Keywords
This publication has 16 references indexed in Scilit:
- Oral transmucosal fentanyl citrate: a novel agent for breakthrough pain related to cancerExpert Review of Neurotherapeutics, 2002
- Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer painBMJ, 2001
- Donepezil in the Treatment of Opioid-Induced SedationJournal of Pain and Symptom Management, 2001
- Transdermal FentanylDrugs, 2001
- Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) dosesAmerican Journal of Hospice and Palliative Medicine®, 2000
- An international survey of cancer pain characteristics and syndromesPain, 1999
- The Relative Potency of Oral Transmucosal Fentanyl Citrate Compared with Intravenous Morphine in the Treatment of Moderate to Severe Postoperative PainAnesthesia & Analgesia, 1999
- The physical examination in cancer pain assessmentSeminars in Oncology Nursing, 1997
- The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective reviewJournal of Pain and Symptom Management, 1994
- Breakthrough pain: definition, prevalence and characteristicsPain, 1990